MetLife (MET)
(Delayed Data from NYSE)
$81.79 USD
+0.01 (0.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $81.78 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.79 USD
+0.01 (0.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $81.78 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
Zacks News
MetLife (MET) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
MetLife's (MET) fourth-quarter results are likely to reflect lower interest rates and higher COVID-19 related claims, partly offset by strong underwriting margins.
Hartford Financial (HIG) Launches Plan for Mental Health
by Zacks Equity Research
Hartford Financial (HIG) introduces a plan to ease the financial stress of people suffering mental health illnesses.
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts
Top Stock Reports for Novartis, QUALCOMM & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), QUALCOMM (QCOM), and Accenture (ACN).
Aflac (AFL) Grows Product Menu Via New Dental & Vision Offers
by Zacks Equity Research
Aflac (AFL) introduces a dental and vision insurance package, thereby widening its product portfolio in the U.S. segment.
MetLife (MET) Unit to Reinsure Legal & General's Longevity Risk
by Zacks Equity Research
MetLife's (MET) subsidiary inscribes four agreements in a bid to foray deeper into the U.K. longevity risk transfer market.
Here's Why Hartford Financial (HIG) Stock is an Attractive Bet Now
by Zacks Equity Research
Hartford Financial (HIG) remains well-poised for growth on the back of impressive performance in Commercial Lines business and sound capital position.
AIG Declines 27% Year to Date: Will It Recover in 2021?
by Zacks Equity Research
AIG has undertaken a host of initiatives including dispositions, which raises hopes for the next year following a dismal period of COVID-19 induced business loss.
Hartford Financial (HIG) Unveils Share Buyback Program Worth $1.5B
by Zacks Equity Research
Hartford Financial's (HIG) board raises share buyback authorization, which showcases its sound financial standing and constant efforts to support prudent capital deployment.
Aflac (AFL) Down 13% in 2020: Will It Bounce Back in 2021?
by Zacks Equity Research
A slew of initiatives recently taken by Aflac (AFL) should aid the stock in 2021 after suffering from COVID-led business loss in 2020.
MetLife (MET) Dips 5% Year to Date: Will it Recover in 2021?
by Zacks Equity Research
Strategic initiatives, such as acquisitions and dispositions, strong business and a gradually improving economic environment will drive MetLife's (MET) shares in 2021.
MetLife (MET) Announces Share Buyback Program Worth $3B
by Zacks Equity Research
MetLife's (MET) board raises share buyback authorization, which reflects its strong financial position and constant efforts to support prudent capital deployment.
MetLife (MET) to Sell Auto & Home Units to Streamline Business
by Zacks Equity Research
MetLife (MET) is working toward shedding the home and auto business from its portfolio and penetrating the domain of life and health insurance and other benefits offerings.
Why Is MetLife (MET) Up 16% Since Last Earnings Report?
by Zacks Equity Research
MetLife (MET) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MetLife's (MET) Business Restructuring on Track for Efficiency
by Zacks Equity Research
MetLife (MET) is reportedly considering the sale of its property and casualty business to focus on more profitable areas.
AIG's Q3 Earnings Beat Estimates & Grow Y/Y, Revenues Miss
by Zacks Equity Research
AIG's third-quarter results reflect premium rate increases across the commercial lines business and reduced costs, partly offset by lower revenues.
Brighthouse (BHF) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Brighthouse Financial's (BHF) third-quarter results reflect growth in annuity and life sales, partly offset by higher expenses.
Allstate's (ALL) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allstate's (ALL) Q3 earnings reflect an increase in premiums and higher expenses due to restructuring charges.
MetLife (MET) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
MetLife's (MET) third-quarter results reflect sound underwriting results and reduced costs, partly offset by muted revenues.
MetLife (MET) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
MetLife (MET) delivered earnings and revenue surprises of 4.85% and 3.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Insurance Stock Q3 Earnings Due on Nov 4: MET, ALL & More
by Zacks Equity Research
Third-quarter results of ALL, MET, LNC, SLF and FNF are likely to reflect improved pricing, strong retention and stable new businesses, partially offset by cat losses and a lower interest rate.
What's in Store for MetLife's (MET) This Earnings Season?
by Zacks Equity Research
Most segments of MetLife (MET) in Q3 are likely to have fared poorly with a drop in adjusted premiums, fees and other revenues. Low interest rates might have dragged down investment income.
6 Multiline Insurers to Watch Out for Amid Operational Challenges
by Tanuka De
Better pricing, product redesigns and increased adoption of technology are expected to aid multiline insurers like CI, MET, CNO, HMN, ORI, and MTG. However, a low-rate environment remains a headwind.
MetLife (MET) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
MetLife (MET) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy MetLife (MET) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.